2026 China Organoid, Organ-on-a-Chip Technology and Application Development Forum

2026 China Organoid, Gene Editing and Organ-on-a-Chip Technology Innovation Exhibition (2026 Guangzhou Organoid Conference)

Exhibition Dates: November 5-7, 2026

Venue: Guangzhou Health Ark Convention and Exhibition Center

Registration: 15889977720 Shu Rong (WeChat linked)

Email: zhishenzhanlan@163.com

Conference Highlights:

For the first time, "Organoids and Organ-on-a-Chip" have been written into the national "15th Five-Year Plan," marking a strategic opportunity for life sciences and medicine. In March 2026, the "Outline of the 15th Five-Year Plan for National Economic and Social Development of the People's Republic of China (Draft)" was officially released. In the frontier research direction of "Life Sciences and Biotechnology," it explicitly listed "Organoids and Organ-on-a-Chip" alongside gene editing, molecular precision delivery, and cell programming as key national tasks, requiring the advanced deployment of major national science and technology projects oriented towards 2035. Since May 1, 2026, the "Regulations on the Management of Clinical Research and Clinical Transformation Application of New Biomedical Technologies" has been officially implemented, marking the first establishment of a systematic and comprehensive legal management system in China's frontier technology fields such as stem cells, immune cells, gene editing, and regenerative medicine.

I. Conference Theme

From Model to Clinic, From Editing to Cure — The Paradigm Revolution in Biomedical Infrastructure

II. Conference

Time and Location

November 5-7, 2026

Guangzhou Health Ark Convention and Exhibition Center

III. Organizational Structure

Organizer:

Guangdong Integrated Life Health Technology Center

Co-organizers:

Stem Cell and Regenerative Medicine Working Committee of China Association for the Promotion of Food and Drug Safety

Guangdong Association for High-Quality Development of Biomedical Industry

Guangzhou Biotechnology Industry Alliance

Contractor:

Guangzhou Chuangmai Exhibition Planning Co., Ltd.

Guangzhou Zhishen Exhibition Co., Ltd.

IV. Three Major Sections, Full Chain Coverage

The conference will feature a full-chain layout of "Frontier Research + Technological Innovation + Industrial Application," focusing on the latest progress of organoids and organ-on-a-chip in disease modeling, drug discovery, precision medicine, and regenerative medicine, with multiple thematic sub-forums. Discussion topics include but are not limited to:

· Organoid culture technology systems and standardization construction

· Tumor organoid construction and drug sensitivity testing applications

· Development and standardization of organ-on-a-chip/micro-physiological systems

· Construction and translational application of organoid biobanks

· Regulatory applications of organoid technology in new drug toxicology evaluation

· Standardization construction of living organoid biobanks and clinical translation pathways

· Integration of biological 3D printing with organoids and organ-on-a-chip

Focusing on original innovation and therapy development in gene editing technology, with in-depth discussions on regulatory frontiers in major regions such as China, the US, and Europe. Discussion topics include but are not limited to:

· Development and optimization of CRISPR/Cas9 and novel gene editing tools

· Clinical progress of gene editing therapies in rare diseases, oncology, ophthalmology, etc.

· Combined application of gene editing and organoid models (for target validation and efficacy evaluation)

· Development of next-generation editing technologies such as base editing and prime editing

· Breakthroughs in gene therapy delivery systems (AAV, LNP, virus-like particles, etc.)

· Construction of safety and ethical regulatory systems for gene editing technology

Focusing on the industrialization paths and ecosystem construction of the three major technologies, with industry experts and investors discussing hot topics in industrialization. Discussion topics include but are not limited to:

· New models for innovative drug discovery driven by organoids + organ-on-a-chip

· Synergistic applications of gene editing in cell therapy and mRNA therapy

· Key technical equipment such as microfluidics, AI automation, and biological imaging

· Quality improvement and upgrading of CRO/CDMO services

· Investment and financing dynamics in biomedicine and industrial park cooperation models

V. [Supporting Activities]

The conference will be held concurrently with:

· Exhibition: Special exhibition zones for organoids, gene editing, and organ-on-a-chip technologies, concentrating on the display of cutting-edge products, technologies, and equipment.

· Summit Forum: Main forum conference reports + parallel sub-forums/satellite meetings.

· Business Matching Meeting: Building a platform for precise matching between enterprises, investment institutions, and upstream and downstream supply chains.

· Project Roadshow: Selecting high-quality innovation and entrepreneurship projects to connect with capital and technical cooperation.

· New Product Launch: Providing a platform for industry innovative enterprises to launch new products.

· Awards Ceremony: Presenting industry honors such as "Annual Innovative Technology Award," "Annual Leading Enterprise Award," and "Young Scientist Award."

VI. Exhibition Scope:

I. Organoid and Organ-on-a-Chip Zone

1. Core Technologies: 2D/3D cell culture, microfluidic chips, microfluidic droplet technology, 3D bioprinting, organ-on-a-chip, organoid chips, biomaterials, nanotechnology, etc.

2. Products and Reagents: Scaffold materials such as matrix gel/collagen/hydrogel, supporting reagents such as cytokines/growth factors/induction differentiation reagents/digestive enzymes, full-process medium kits for dissociation/expansion/cryopreservation/resuscitation, multi-organ and human tissue biomimetic micro-tissue models.

3. Equipment and Instruments: Biological 3D printers, high-content imaging systems, microfluidic automated control and analysis systems, automated high-throughput organoid culture and screening systems, intelligent real-time monitoring systems, AI-empowered organoid all-in-one machines, microscopic imaging equipment, flow cytometers, tissue grinders, mass spectrometry systems, as well as cryogenic storage equipment, reactors, etc.

4. Services and Applications: Organoid biobanking and drug sensitivity testing services, customized tumor organoid model construction, efficacy/toxicity evaluation services, CRO/CDMO R&D and production outsourcing services, development of standards for preclinical efficacy testing of organ-on-a-chip.

II. Gene Editing and Gene Therapy Zone

1. Core Technologies: Common editing systems such as CRISPR/Cas9, novel editing systems such as Cpf1, Base Editing, Prime Editing, Epigenome Editing, and large fragment gene editing, etc.

2. Delivery Systems: Viral vectors such as Adeno-Associated Virus (AAV), lentivirus, adenovirus, and non-viral vectors such as Lipid Nanoparticles (LNP), exosomes, virus-like particles, etc.

3. Products and Equipment: Supporting reagents and consumables such as gene synthesis/mRNA/off-target detection, efficient gene transfection systems, cell electroporators, cell counters, bioreactors, etc., as well as related CMC process development and quality control.

4. Services and Applications: Gene editing therapy development and clinical translation services, customized gene editing animal models (e.g., knockout/knock-in/humanized mice), CGT (Cell and Gene Therapy) drug R&D outsourcing services, combined use of gene editing and organoid models for target validation and efficacy evaluation, etc.

III. Supporting Technical Services and Full Industry Chain

1. Research Instruments and Laboratory Equipment: Biochemical analysis instruments, biological imaging systems, biochips, sequencers, mass spectrometers, automated workstations, pipetting systems, high-throughput screening platforms.

2. Reagents and Consumables: High-quality molecular enzymes, cytokines, culture media, serum, nucleic acid removal products, etc.

3. CRO/CDMO Services: Covering Cell and Gene Therapy (CGT) process development, GMP production, Investigational New Drug (IND) application, drug registration processes, etc.< /p>

4. Digitization and Bioinformatics: AI-aided drug screening and target prediction software, bioinformatics analysis platforms, bioinformatics big data analysis, laboratory information systems, etc.

IV. Biomedicine and Clinical Application Category:

Innovative pharmaceutical companies and medical institutions developing gene therapy and cell therapy drugs.

VII. Distinguished Guests for Exchange and Visit

The conference sincerely invites professionals in the following fields to attend for free:

· Experts from national and local drug review and regulatory agencies

· Scholars in relevant fields from research institutes and universities (life sciences, biomedical engineering, pharmacy, medicine, etc.)

· Clinical doctors and researchers in medical institutions

· R&D and management teams of innovative pharmaceutical companies and biotechnology enterprises

· Upstream and downstream enterprises in the organoid, gene editing, and organ-on-a-chip industry chain

· Cell therapy, gene therapy, and mRNA therapy enterprises

· Biomedical investment and financing institutions, industrial park representatives

· CRO/CDMO service agencies and equipment/consumable suppliers

· Industry associations, societies societies, and technology media

Exhibition Fee: Standard Booth 9 sqm / 13,800 RMB

Raw Space Booth: 1,300 RMB / sqm

(Includes standard booth setup for every 9 sqm, company fascia, power socket, a set of tables and chairs, one inquiry desk)

Organizing Committee:

Guangzhou Chuangmai Exhibition Planning Co., Ltd.

Guangzhou Zhishen Exhibition Co., Ltd.

Organizing Committee Office:

Exhibition Inquiry: Shu Rong

Consultation Phone: 15889977720 (WeChat linked)

Email: zhishenzhanlan@163.com